CS
DYN icon

Candriam SCA’s Dyne Therapeutics DYN Stock Holding History

Candriam SCA’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,057,263
Closed -$20.7M – 705
2025
Q4 		$20.7M Buy
1,057,263
+223,341
+27% +$4.23M 0.1% 187
2025
Q3 		$10.5M Buy
833,922
+309,761
+59% +$3.53M 0.06% 267
2025
Q2 		$4.99M Buy
524,161
+60,793
+13% +$669K 0.03% 350
2025
Q1 		$4.85M Buy
463,368
+61,973
+15% +$887K 0.03% 335
2024
Q4 		$9.46M Buy
401,395
+10,439
+3% +$309K 0.05% 268
2024
Q3 		$14M Sell
390,956
-142,317
-27% -$5.66M 0.08% 223
2024
Q2 		$18.8M Sell
533,273
-142,351
-21% -$4.14M 0.11% 181
2024
Q1 		$19.2M Sell
675,624
-88,000
-12% -$1.99M 0.12% 171
2023
Q4 		$10.2M Buy
763,624
+40,000
+6% +$391K 0.07% 248
2023
Q3 		$6.48M Hold
723,624
– – 0.05% 283
2023
Q2 		$8.14M Buy
723,624
+90,000
+14% +$1.06M 0.06% 268
2023
Q1 		$6.72M Hold
633,624
– – 0.05% 313
2022
Q4 		$7.34M Buy
633,624
+220,000
+53% +$2.55M 0.05% 323
2022
Q3 		$5.25M Hold
413,624
– – 0.04% 366
2022
Q2 		$2.84M Buy
413,624
+90,231
+28% +$622K 0.02% 427
2022
Q1 		$3.12M Hold
323,393
– – 0.02% 448
2021
Q4 		$3.85M Hold
323,393
– – 0.02% 407
2021
Q3 		$5.25M Hold
323,393
– – 0.04% 389
2021
Q2 		$6.8M Buy
+323,393
New +$6.08M 0.05% 347

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Candriam SCA's DYN Position: Q1 2026 in Review

Candriam SCA sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 1,057,263 shares — an estimated $20.7M sold.

Candriam SCA first reported a position in DYN in Q2 2021 and held it in 19 quarters. The position peaked at $20.7M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Candriam SCA reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Candriam SCA sold 1,057,263 Dyne Therapeutics shares in Q1 2026, an estimated $20.7M.
  • Candriam SCA first reported a position in Dyne Therapeutics in Q2 2021 and held it in 19 quarters.
  • Candriam SCA's Dyne Therapeutics position peaked at $20.7M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.